IP Library Granted Patent US 8,435,523
Granted Patent B2
US 8,435,523 · App. 12/773,488 · Granted May 7, 2013

Antibodies against nerve growth factor (NGF) with enhanced in vivo stability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,523
App. No.
12/773,488
Granted
May 7, 2013
Kind
B2
Abstract

The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.

Claims (9)

1. An anti-nerve growth factor (NGF) antibody comprising (i) a heavy chain variable region comprising CDRs 1, 2 and 3 comprising the amino acid sequences of SEQ ID NOs: 3, 4 and 5, respectively, (ii) a light chain variable region comprising CDRs 1, 2 and 3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively, and (iii) a human IgG4 constant region, wherein the human IgG4 constant region comprises the amino acid sequence of SEQ ID NO: 10.

2. An anti-nerve growth factor (NGF) antibody comprising (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1, (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2, and (iii) a human IgG4 constant region, wherein the human IgG4 constant region comprises the amino acid sequence of SEQ ID NO: 10.

3. The anti-NGF antibody claim 1 , which comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1.

4. The anti-NGF antibody claim 1 , which comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2.

5. The anti-NGF antibody claim 1 , which is a chimeric, humanized or human antibody.

6. A pharmaceutical composition comprising the anti-NGF antibody of claim 1 and a pharmaceutically acceptable carrier.

7. A kit comprising the anti-NGF antibody of claim 1 and instructions for use of the antibody in treating NGF-related pain.

8. An anti-nerve growth factor (NGF) antibody comprising a human IgG4 constant region, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and comprises a light chain comprising the amino acid sequence of SEQ ID NO: 16.

9. An anti-nerve growth factor (NGF) antibody comprising a human IgG4 constant region, wherein the antibody comprises a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 11, and a light chain encoded by the nucleotide sequence of SEQ ID NO: 14.

Assignments (3)
CHANGE OF NAME Recorded Mar 14, 2014
From: ABBOTT RESEARCH B.V.
To: ABBVIE RESEARCH B.V.
Reel/Frame 032453/0835 →
CHANGE OF NAME Recorded Aug 3, 2012
From: PANGENETICS 110 B.V.
To: ABBOTT RESEARCH B.V.
Reel/Frame 028722/0024 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2010
From: POWELL, JOHN; CASSON, DUNCAN; MAGINN, MARK; LIU, WEI; DUTTA, SANDEEP; BEST, ANDREA; HALL, JERRY A.
To: PANGENECTIS 110 BV
Reel/Frame 024643/0970 →